BIOSYENT INC (RX.CA) Stock Price, Forecast & Analysis
Canada - TSX Venture Exchange - TSX-V:RX - CA0906901081 - Common Stock
RX.CA Key Statistics, Chart & Performance
The current stock price of RX.CA is 12.73 CAD. In the past month the price increased by 4.86%. In the past year, price increased by 14.07%.
RX.CA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| BHC.CA | BAUSCH HEALTH COS INC | 1.82 | 3.53B | ||
| TLRY.CA | TILRAY BRANDS INC | N/A | 1.44B | ||
| CRON.CA | CRONOS GROUP INC | 24 | 1.38B | ||
| DHT-UN.CA | DRI HEALTHCARE TRUST | 7.14 | 885.62M | ||
| GUD.CA | KNIGHT THERAPEUTICS INC | N/A | 600.70M | ||
| WEED.CA | CANOPY GROWTH CORP | N/A | 574.80M | ||
| NGEN.CA | NERVGEN PHARMA CORP | N/A | 564.94M | ||
| CPH.CA | CIPHER PHARMACEUTICALS INC | 16.73 | 382.07M | ||
| TSND.CA | TERRASCEND CORP | N/A | 364.57M | ||
| ACB.CA | AURORA CANNABIS INC | N/A | 324.39M | ||
| HITI.CA | HIGH TIDE INC | N/A | 320.21M | ||
| OGI.CA | ORGANIGRAM GLOBAL INC | N/A | 310.30M |
Related stock screener links
About RX.CA
Company Profile
BioSyent, Inc. is a specialty pharmaceutical company, which engages in the development of pharmaceutical and healthcare products. The company is headquartered in Mississauga, Ontario. The Company, through its wholly owned subsidiaries, BioSyent Pharma Inc., and BioSyent Pharma International Inc., sources, acquires or in-licenses and further develops pharmaceutical and other healthcare products for sale in Canada and certain international markets. Hedley Technologies Ltd., a wholly owned subsidiary, operates the Company’s business marketing biologically and health friendly non-chemical insecticides. The Company’s products include Combogesic, Cathejell, FeraMAX Pd Therapeutic 150, FeraMAX Pd Maintenance 45, FeraMAX Pd Powder 15, Gelclair, Inofolic, Proktis-M, RepaGyn, and Tibella. Combogesic is for the short-term management of mild to moderate acute pain and the reduction of fever in adults. FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia. FeraMAX Pd Maintenance 45 is a chewable supplement with iron plus vitamin B12 and vitamin C for the prevention of iron deficiency anemia.
Company Info
BIOSYENT INC
2476 Argentia Road, Suite 402
Mississauga ONTARIO L5N 6M1 CA
CEO: Rene Goehrum
Employees: 0
Phone: 18884390013
BIOSYENT INC / RX.CA FAQ
What does RX do?
BioSyent, Inc. is a specialty pharmaceutical company, which engages in the development of pharmaceutical and healthcare products. The company is headquartered in Mississauga, Ontario. The Company, through its wholly owned subsidiaries, BioSyent Pharma Inc., and BioSyent Pharma International Inc., sources, acquires or in-licenses and further develops pharmaceutical and other healthcare products for sale in Canada and certain international markets. Hedley Technologies Ltd., a wholly owned subsidiary, operates the Company’s business marketing biologically and health friendly non-chemical insecticides. The Company’s products include Combogesic, Cathejell, FeraMAX Pd Therapeutic 150, FeraMAX Pd Maintenance 45, FeraMAX Pd Powder 15, Gelclair, Inofolic, Proktis-M, RepaGyn, and Tibella. Combogesic is for the short-term management of mild to moderate acute pain and the reduction of fever in adults. FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia. FeraMAX Pd Maintenance 45 is a chewable supplement with iron plus vitamin B12 and vitamin C for the prevention of iron deficiency anemia.
What is the current price of RX stock?
The current stock price of RX.CA is 12.73 CAD. The price decreased by -1.24% in the last trading session.
Does RX stock pay dividends?
BIOSYENT INC (RX.CA) has a dividend yield of 1.56%. The yearly dividend amount is currently 0.18.
What is the ChartMill rating of BIOSYENT INC stock?
RX.CA has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 8 out of 10.
Can you provide the upcoming dividend date for BIOSYENT INC?
The next ex-dividend date for BIOSYENT INC (RX.CA) is November 28, 2025.
What is the market capitalization of RX stock?
BIOSYENT INC (RX.CA) has a market capitalization of 146.14M CAD. This makes RX.CA a Micro Cap stock.
Can you provide the upcoming earnings date for BIOSYENT INC?
BIOSYENT INC (RX.CA) will report earnings on 2026-03-11.
RX.CA Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to RX.CA. When comparing the yearly performance of all stocks, RX.CA turns out to be only a medium performer in the overall market: it outperformed 58.75% of all stocks.
RX.CA Fundamental Analysis
ChartMill assigns a fundamental rating of 8 / 10 to RX.CA. RX.CA gets an excellent profitability rating and is at the same time showing great financial health properties.
RX.CA Financial Highlights
Over the last trailing twelve months RX.CA reported a non-GAAP Earnings per Share(EPS) of 0.62. The EPS increased by 24.84% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 20.47% | ||
| ROA | 18.07% | ||
| ROE | 21.64% | ||
| Debt/Equity | 0.02 |
RX.CA Forecast & Estimates
7 analysts have analysed RX.CA and the average price target is 13.77 CAD. This implies a price increase of 8.17% is expected in the next year compared to the current price of 12.73.
For the next year, analysts expect an EPS growth of 20.96% and a revenue growth 23.16% for RX.CA